Literature DB >> 8704976

The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum.

Anders Sjöstedt1,2,3, Robert J North3, J Wayne Conlan3.   

Abstract

The present study was conducted to determine the extent to which the cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) are required to protect against primary or secondary murine tularaemia caused by the live vaccine strain of the facultative intracellular bacterium Francisella tularensis. It is shown that non-immune mice treated with neutralizing monoclonal antibodies (mAbs) against TNF-alpha and IFN-gamma are rendered defenceless against otherwise sublethal intravenous inocula of the bacterium. Treatment with either of the anti-cytokine mAbs resulted in even a very small inoculum of 500 c.f.u. of the pathogen multiplying unrestrictedly in the livers, spleens and lungs of non-immune mice to rapidly reach lethal numbers. By contrast, Francisella-immune mice treated with either of the mAbs remained capable of resolving secondary infection with 50-fold larger inocula. However, the need for TNF-alpha and IFN-gamma for controlling secondary tularaemia became critical when challenge inocula exceeded 10(6) c.f.u. Overall, the results imply that different defence mechanisms operate to control primary versus secondary murine tularaemia. Additionally, they show that the need for TNF-alpha and IFN-gamma to combat secondary infection depends on the size of the challenge inoculum.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704976     DOI: 10.1099/13500872-142-6-1369

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  40 in total

1.  Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity.

Authors:  C M Bosio; K L Elkins
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.

Authors:  H M El Sahly; R L Atmar; S M Patel; J M Wells; T Cate; M Ho; K Guo; M F Pasetti; D E Lewis; M B Sztein; W A Keitel
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

3.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

4.  OpiA, a Type Six Secretion System Substrate, Localizes to the Cell Pole and Plays a Role in Bacterial Growth and Viability in Francisella tularensis LVS.

Authors:  Stuart Cantlay; Kristen Haggerty; Joseph Horzempa
Journal:  J Bacteriol       Date:  2020-06-25       Impact factor: 3.490

5.  Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG.

Authors:  Helena Lindgren; Hua Shen; Carl Zingmark; Igor Golovliov; Wayne Conlan; Anders Sjöstedt
Journal:  Infect Immun       Date:  2007-01-08       Impact factor: 3.441

6.  T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria.

Authors:  Carmen M Collazo; Anda I Meierovics; Roberto De Pascalis; Terry H Wu; C Rick Lyons; Karen L Elkins
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

7.  Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection.

Authors:  Dennis W Metzger; Sharon L Salmon; Girish Kirimanjeswara
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

8.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

9.  Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.

Authors:  Hua Shen; Gregory Harris; Wangxue Chen; Anders Sjostedt; Patrik Ryden; Wayne Conlan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

10.  Epitope-based vaccination against pneumonic tularemia.

Authors:  Stephen H Gregory; Stephanie Mott; Jennifer Phung; Jinhee Lee; Leonard Moise; Julie A McMurry; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.